Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

05 April 2016 European Medicines Agency Supports Maintaining Orphan Designation for IDELVION®

CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]. IDELVION® is CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.

> Read More
21 March 2016 IDELVION® for Hemophilia B Now Available in the U.S.

CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting recombinant albumin fusion protein for treating hemophilia B, is now available nationwide.

> Read More
15 March 2016 CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies

A new webinar series addresses the unique needs of young adults living with Primary Immunodeficiency at a critical time when they are transitioning from teen to adulthood and taking responsibility for their own care.

> Read More
09 March 2016 CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives

Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest round of LEAD Grant awards. CSL Behring established the LEAD grant program in 2008 to help support the important advocacy work of patient groups in tackling complex legislative and public policy issues.

> Read More
04 March 2016 U.S. FDA Approves CSL Behring’s IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of hemophilia B.

> Read More
Page 4 of 52 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+